Chunxiao Xu

TL;DR: These studies show that miR-122, a 22-nucleotide microRNA, is derived from a liver-specific non-coding polyadenylated RNA transcribed from the gene hcr, which may be a specific mRNA target, CAT-1, which is expressed in all mammaliantissues but with lower levels in adult liver.

TL;DR: Rational discovery of EAI045 is described, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild type receptor and shows dramatic synergy of cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to theAllosteric agent.

TL;DR: Findings suggest that gain-of-function mutations in DDR2 are important oncogenic events and are amenable to therapy with dasatinib, and provide a rationale for designing clinical trials with the FDA-approved drug d asatinib in patients with lung SCCs.

TL;DR: It is demonstrated that concomitant loss of either p53 or Lkb1, two clinically relevant tumour suppressors, markedly impaired the response of Kras-mutant cancers to docetaxel monotherapy, highlighting the rationale for synchronous co-clinical trials.

TL;DR: Preclinical data demonstrate that simultaneous blockade of the PD-L1 and TGF-β pathways by M7824 elicits potent and superior antitumor activity relative to monotherapies.